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Abstract
The pathophysiology of irritable bowel syndrome (IBS) is not completely
understood. However, several factors are known to play a role in
pathophysiology of IBS such as genetics, diet, gut microbiota, gut endocrine cells,
stress and low-grade inflammation. Understanding the pathophysiology of IBS
may open the way for new treatment approaches. Low density of intestinal stem
cells and low differentiation toward enteroendocrine cells has been reported
recently in patients with IBS. These abnormalities are believed to be the cause of
the low density of enteroendocrine cells seen in patients with IBS.
Enteroendocrine cells regulate gastrointestinal motility, secretion, absorption and
visceral sensitivity. Gastrointestinal dysmotility, abnormal absorption/secretion
and visceral hypersensitivity are all seen in patients with IBS and haven been
attributed to the low density the intestinal enteroendocrine cells in these patients.
The present review conducted a literature search in Medline (PubMed) covering
the last ten years until November 2019, where articles in English were included.
Articles about the intestinal stem cells and their possible role in the
pathophysiology of IBS are discussed in the present review. The present review
discusses the assumption that intestinal stem cells play a central role in the
pathophysiology of IBS and that the other factors known to contribute to the
pathophysiology of IBS such as genetics, diet gut microbiota, stress, and low-
grade inflammation exert their effects through affecting the intestinal stem cells.
It reports further the data that support this assumption on genetics, diet, gut
microbiota, stress with depletion of glutamine, and inflammation.
Key words: Diet; Gut enteroendocrine cells; Gut microbiota; Low grade inflammation;
Stress
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Core tip: The pathophysiology of irritable bowel syndrome (IBS) is not completely
understood. Understanding the pathophysiology of IBS may enable us to find an
effective treatment for this disorder. The density of intestinal stem cells is low in patients
with IBS. Moreover, the differentiation of stem cells into enteroendocrine cells is
abnormal. It seems that these abnormalities in intestinal stem cells is the cause of the low
density of enteroendocrine cells seen in patients with IBS. It is believed that the low
density of enteroendocrine cells is behind the gastrointestinal dysmotility, abnormal
secretion/absorption and hypersensitivity observed in patients with IBS. This review
presents the observations that suggest that the factors known to contribute to the
pathophysiology of IBS may exert their effects through affecting the intestinal stem
cells.
Citation: El-Salhy M. Possible role of intestinal stem cells in the pathophysiology of irritable




Irritable bowel syndrome (IBS) is a wide spread condition affecting 12.1% of the world
population[1,2]. The prevalence of IBS differs considerably between different parts of
the world with the lowest prevalence in Asia and the highest in South America[1]. The
cardinal symptom of IBS is intermittent abdominal pain accompanied by altered
bowel  habits  and  abdominal  bloating/distention[3].  There  is  no  biochemical,
radiological or clinical test/examination for diagnosing IBS and the IBS diagnosis is
based on symptoms assessment[4]. IBS reduces significantly the patients’ quality of life
in the same degree as major chronic diseases such heart failure, renal failure, diabetes,
and inflammatory bowel disease[2,3]. It has been reported that 12%-14% of primary care
patient  visit,  and 28% of  referrals  to  gastroenterologists  are  IBS  patients[5-7]  and
consequently IBS patients are more common in the healthcare than patients with
diabetes, hypertension or asthma[8,9]. There is no effective treatment for IBS and the
available treatment in clinic is directed to symptom relief[4].
Several  factors are known to play pivot role in pathophysiology of  IBS.  These
factors are genetics, diet, gut microbiota, gut endocrine cells, stress and low-grade
inflammation[2,10].  Abnormalities  in  the  intestinal  stem  cells  has  been  reported
recently[11-13]. The present review aimed at discussing the possibility that the factors
known to contribute to the pathophysiology of IBS may exert their effects through
affecting the intestinal stem cells. The present review conducted a literature search in
MEDLINE (PubMed) covering the last ten years until November 2019, where articles
in English were included. Articles about the intestinal stem cells and their possible
role in the pathophysiology of IBS are discussed.
FCACORS INVOLVED IN THE PATHOPHYSIOLOGY OF IBS
Genetics
Studies of family history and family cluster as well as twin studies provided strong
evidences that IBS is hereditary[14-21]. However, the possible mutant gene(s) responsible
for IBS is/are not found yet[2].
Diet
Patients with IBS avoid certain food items as they believe they worsen/trigger their
symptoms[22-26].  However,  there is  no difference in intake of  calories,  or the meal
patterns between IBS patients and community controls[23,27,28].
The  effect  of  diet  on  IBS  symptoms  cannot  be  explained  by  food  allergy/
intolerance[29]. However, it is generally accepted that poorly absorbed carbohydrates
and fibers play an important role in development IBS symptoms[29,30]. The intake of
low fermentable oligo-, di-, monosaccharides and polyols-diet and National Institute
for Health and Care Excellence-modified diet improve both symptoms and quality of
life in IBS patients[22,29,31,32]. However, a recent review and meta-analysis showed that
there  is  very  low  quality  evidence  showing  that  low  fermentable  oligo-,  di-,
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monosaccharides and polyols diet reliefs IBS symptoms[33].
Based  on  a  case  report  published  in  1978,  non-celiac  gluten  sensitivity  was
coined[34-36]. In this case, a patient without celiac disease, suffered from abdominal pain
and diarrhea who experienced symptoms improved when she used gluten-free diet.
Several studies showed that withdrawal of wheat products in patients with non-celiac
IBS-like symptoms improve these symptoms[37-42]. However, a double-blind placebo-
controlled study showed that it is fructan in the wheat rather than gluten that trigger
IBS  symptoms[43].  In  a  recently  published  meta-analysis  concluded that  there  is
insufficient evidence that gluten-free diet improves IBS symptoms[33].
Gut microbiota
The gastrointestinal microbiota comprises 12 different bacteria phyla, but most of the
gut  bacteria  belongs  to  the  Proteobacteria,  Firmicutes,  Actinobacteria  and
Bacteroidetes[44,45]. The anaerobic Firmicutes and Bacteroidetes phyla dominate the
bacterial population in the intestinal of healthy adults, with a few members from of
the Proteobacteria and Actinobacteria phyla[45,46]. A low microbial diversity in the gut
(dysbiosis) has been reported to be associated with several diseases[47,48].
In  healthy  subjects,  the  intestinal  microbiota  composition  is  affected  by  the
individual genetic composition and environmental factors one is exposed for[44,48]. The
intestinal microbiota in IBS patients differs from that of healthy subjects[48-51], and have
a lower diversity (dysbiosis)[48-51]. It is believed that this difference in the intestinal
microbiota plays a pivot role in the pathophysiology of IBS[49].
Gastrointestinal endocrine cells
The gastrointestinal endocrine cells are scattered in-between the epithelial cells facing
the gut lumen (Figure 1)[52-54].These cells are localized to the stomach, small-and large
intestine[53]. Among the different segments of the gastrointestinal tract the density of
the endocrine cells is highest in the duodenum (Figure 2)[25]. These cells secret over 10
different hormones that interact and integrate with the enteric, autonomic and central
nervous system to regulate: Gastrointestinal motility, secretion of enzymes and bile
acid, absorption of nutrients, visceral sensation, gastrointestinal cell proliferation,
local immune defense and appetite[3,22,52,55-69]. These cells have sensory microvilli that
project into the gastrointestinal lumen that sense gastrointestinal lumen contents and
respond by releasing their hormones into the lamina propria[70-82]. These hormones can
act locally on the nearby structures (paracrine mode of action) or reach the blood
stream and act on far structure (endocrine mode of action)[70-82].
Several abnormalities in different endocrine cell types of the stomach, small- and
large intestine have been described in IBS patients (Figure 3)[53,83-97]. Generally, IBS
patients have a lower gut endocrine cell density than healthy subjects[52].
Stress
Stress  is  defined  as  an  acute  threat,  real  or  perceived,  to  the  homeostasis  of  an
organism[10]. Stress is a known factor that trigger/worsen the IBS symptoms[98]. The
exact mechanisms by which stress affects IBS are not exactly known. However, the
negative effect of stress on IBS symptoms is believed to be caused by an interaction
between the gut and the central nervous system (gut-brain axis)[10].
Low grade inflammation
Intestinal low-grade inflammation is believed to be a factor that contribute to the
pathophysiology of IBS[86]. Lowgrade inflammation in the intestinal mucosa occurs
only in a subset of IBS, i.e.,  post-infectious IBS, but not in sporadic (non-specific)
IBS[86,99-102].
THE ROLE OF INTESTINAL STEM CELLS IN THE
PATHOPHYSIOLOGY OF IBS
Intestinal stem cells
Each intestinal crypt contains four to six pluripotent (stem) cells[103]. Stem cell perform
2 activities, namely self-renewal by dividing into identical stem cell (clonogeny) to
maintain a  constant  number of  stem cells  and differentiation progeny[103].  In  the
differentiation progeny, the stem cells differentiate into all cell types of the villus
epithelium through 2 cell lineages: The secretory lineage giving raise to goblet cells,
endocrine cells and Paneth cells, and the absorptive lineage giving raise to absorptive
enterocytes.  This  differentiation  takes  place  through  a  series  of  precursors
(progenitors) (Figure 4)[68,69,104-112].
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Figure 1
Figure 1  Schematic illustration of the enteroendocrine cells and their anatomic relation to the enteric nervous system. The enteroendocrine cells are
scattered among the epithelial cells lining the intestinal lumen. They interact and intergrade with each other’s and with enteric nervous system. Reproduced from El-
Salhy et al[54] by permission of the authors and the publisher.
The relation between the abnormalities in intestinal stem cells and enteroendocrine
cells
As mentioned previously, the densities of the gastrointestinal endocrine cells are
lower  than  that  of  healthy  subjects[53,83-97].  The  cell  density  of  Musashi  1,  and
neurogenin 3 immunoreactive cells in the small and large intestine of patients with
IBS are lower than that of healthy subjects (Figures 5 and 6)[11-13]. Musashi 1 is marker
for intestinal stem cells and their early progeny, and neurogenin 3 is expressed in
early intestinal endocrine cell progenitors originated from stem cells[103,113-118]. The low
densities of enteroendocrine cells  in patients with IBS could be explained by the
abnormalities in intestinal stem cells[119]. Thus, low densities of Msi-1 and NEUROG3
small and large intestine in IBS patients indicate that the intestinal stem cells in these
patients exhibit reduced clonogenic activity and low differentiation progeny toward
endocrine cells[119,120].
HYPOTHESIS
Based on the data presented above, one may hypothesized that IBS patients may have
a gene mutation controlling the number of the stem cells and/or NEUROG3 gene
mutation. Furthermore, environmental factors such as diet, inflammation, stress and
gut microbiota may affect the stem cells and their progeny (Figure 7). This hypothesis
gets support from the following facts: (1) Low density of intestinal endocrine cells has
been described in patients with congenital  malabsorptive diarrhoea,  which is  an
autosomal recessive disorder[121]. The low density of intestinal endocrine cells in this
disorder is caused by loss-of-function mutations in NEUROG3 gene[121]. Similarly, low
density of intestinal endocrine cells has been observed in small-intestine allograft
rejection,  and  in  NEUROG3-knockout  mice[117,120].  The  low  density  of  intestinal
endocrine cells in these conditions was associated with a reduction in number of
intestinal neurogenin 3 cells[117,120]; (2) Changing from the common Norwegian diet to a
National Institute for Health and Care Excellence-modified diet, which improved
symptoms and quality of life in IBS patients is associated with changes in the densities
of gastrointestinal cells[91,122-127]; (3) Modulation of the intestinal microbiota by fecal
microbiota  transplantation  improved  both  symptoms  and  the  quality  of  life  in
patients  with IBS[128].  This  improvement was accompanied by a  change in in  the
densities of enteroendocrine cells[128];  (4) Glutamine is the main energy source for
intestinal  enterocytes and plays a major role in intestinal  homeostasis  and other
physiological functions[129-133]. Stress, infection or inflammation cause a depletion of
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Figure 2
Figure 2  The density of gut endocrine cells as detected by chromogranin a immunoreactivity. Reproduced
from El-Salhy et al[25] by permission of the authors and the publisher.
glutamine[129-133]  In  a  randomized  placebo-controlled  study,  dietary  glutamine
supplements improved symptoms in patients with post-infectious IBS[134]. Glutamine
have a trophic effect on the intestinal stem cells and promotes stem cell differentia-
tion[129,135,136]. One may speculate that stress results in the depletion of glutamine, which
causes disturbance in the differentiation of the intestinal cells. This in turn would
cause low density in enteroendocrine cells and the development of IBS symptoms;
and (5) In animal models of human ulcerative colitis and Crohn’s disease, the changes
in enteroendocrine cells have been found to be strongly correlated with changes in the
intestinal stem cells and their differentiation progeny toward intestinal endocrine
cells[137,138].
CLINICAL IMPLICATIONS
Assuming that IBS is caused by abnormalities in stem cells, which in turn caused by
genetic and environmental factors, intestinal stem cell transplantation might be an
effective tool in the treatment of IBS.
CONCLUSION
The intestinal stem cells appear to play a central role in the pathophysiology of IBS.
Factors that are known to be involved in the pathophysiology of IBS exert their effects
probably through affecting the intestinal stem cells.
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Figure 3
Figure 3  Chromogranin immunoreactive cells in the duodenum of a healthy subject and of a patient with irritable bowel syndrome. A: Chromogranin
immunoreactive cells in the duodenum of a healthy subject; B: Chromogranin immunoreactive cells in the duodenum of a patient with irritable bowel syndrome (IBS);
C: Chromogranin A cells in the colon of a healthy control; D: Chromogranin A cells in the colon of a patient with IBS. Chromogranin A is a common marker for
enteroendocrine cells. The density of Chromogranin A in the duodenum and colon of patients with IBS is lower than that of healthy subjects.
Figure 4
Figure 4  The intestinal stem cell divides into 2 identical cells (clonogeny). One of these cells remain inactive, while the other stem cell differentiates into all cell
types of the villus epithelium through 2 cell lineages: The secretory lineage giving raise to goblet cells, endocrine cells and Paneth cells, and the absorptive lineage
giving raise to absorptive enterocytes. This differentiation occurs through a series of progenitors. The observations that the density of stem cells and progenitors for
enteroendocrine cells, led to the assumption of gene mutations affecting the stem cell and neurogenin 3 gene.
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Figure 5
Figure 5  Musashi 1 immunoreactive cells in duodenum. A: A healthy subject; B: A patient with irritable bowel syndrome (IBS). Musashi 1 is a marker for intestinal
stem cells and their early progeny. The density of Musahi 1 cells in healthy subjects is higher than that of the IBS patients. Furthermore, Musashi 1 cells in healthy
subjects appear to have more proliferation activity than that of IBS patients.
Figure 6
Figure 6  Neurogenin 3 immunoreactive cells in the duodenum. A: A healthy control; B: A patient with irritable bowel syndrome. Neurogenin 3 is expressed in the
nuclei (brown) of early intestinal endocrine cell progenitors. The healthy subjects have higher density of neurogenin 3 than irritable bowel syndrome patients.
Figure 7
Figure 7  Schematic drawing to illustrate the hypothesis that intestinal stem cells play a central role in the pathophysiology of irritable bowel syndrome.
The abnormalities in the intestinal stem cells can be caused by gene mutation or by environmental factors such as diet, intestinal microbiota, stress and low-grade
inflammation.
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